A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants with Relapsed or Refractory Non-Hodgkin Lymphoma

Inclusion Criteria:
*  Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
*  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
*  At least 1 measurable lesion per Lugano criteria.
*  Tumor tissue is available.
*  Adequate organ function

Exclusion Criteria:
*  T-cell lymphoma
*  CLL or SL
*  Burkitt lymphoma and high-grade B-cell lymphoma
*  CNS involvement
*  Peripheral neuropathy \> Grade 2
*  Uncontrolled medical conditions
*  Viral infections